Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 890438, 5 pages
Case Report

Clinical Lessons to Be Learned from Patients Developing Chronic Myeloid Leukemia While on Immunosuppressive Therapy after Solid Organ Transplantation: Yet Another Case after Orthotopic Heart Transplantation

1Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Universitätsmedizin Berlin, Campus Mitte Charité, Schumannstraße 20/21, 10117 Berlin, Germany
2Deutsches Herzzentrum Berlin, Abteilung für Herz-, Thorax- und Gefäßchirurgie, Augustenburger Platz 1, 13353 Berlin, Germany
3Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Universitätsmedizin Berlin, Campus Virchow Charité, Augustenburger Platz 1, 13353 Berlin, Germany

Received 31 August 2014; Revised 23 October 2014; Accepted 24 October 2014; Published 16 November 2014

Academic Editor: Kazunori Nakase

Copyright © 2014 Christian Oberender et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chronic myeloid leukemia developing after transplantation of solid organs and concomitant immunosuppression is a rare but still significant clinical phenomenon. We here describe an additional case of a 62-year-old male patient developing CML after orthotopic heart transplantation and medication with cyclosporine A, mofetil-mycophenolate, and steroids. Initial antileukemic therapy was imatinib at a standard dose and within 15 months of therapy a complete cytogenetic response was noted. In this report we discuss the clinical implications of these rare but biologically important cases.